Eric Laïlle
About Eric Laïlle
Eric Laïlle is a Senior Clinical Research Scientist at Bristol Myers Squibb in Overland Park, Kansas, with extensive experience in clinical pharmacology and pharmacokinetics.
Company
Eric Laïlle is currently employed at Bristol Myers Squibb, a globally recognized biopharmaceutical company. He is based in Overland Park, Kansas, United States.
Title
Eric Laïlle holds the title of Senior Clinical Research Scientist at Bristol Myers Squibb. His responsibilities include leading clinical research projects and contributing to the development of new pharmaceutical products.
Education and Expertise
Eric Laïlle has a robust educational background in pharmacokinetics and biochemistry. He studied at Université de Bordeaux in France, where he achieved a DESS de Pharmacocinétique Approfondie Appliquée au Développement des Médicaments. He also studied at Université Paul Sabatier in Toulouse, France, earning a Diplome Universitaire de Pharmacocinétique and a Maîtrise de Biochimie. His academic credentials have provided him with a strong foundation in drug development and pharmacokinetics.
Background
Eric Laïlle has extensive experience in the field of clinical pharmacology and pharmacokinetics. Prior to his role at Bristol Myers Squibb, he worked at Celgene for over a decade. From 2006 to 2017, he served as Manager of Clinical Pharmacology and Pharmacokinetics. He then transitioned to the role of Clinical Research Scientist from 2017 to 2019, before moving to Bristol Myers Squibb.
Achievements
Eric Laïlle has made significant contributions to the field of pharmaceutical research. He played a pivotal role in the development of Onureg (CC 486; oral azacitidine), which received FDA approval on 01 September 2020, and subsequently gained approval from several other agencies in 2021. Additionally, he was a key clinical scientist in the phase 3 AG-221-AML-004 study, which assessed the efficacy and safety of AG-221 (CC-90007) in treating older subjects with late-stage acute myeloid leukemia (AML) harboring an IDH-2 mutation.